Literature DB >> 25899076

Long-acting injectable hormonal dosage forms for contraception.

Linfeng Wu1, Dileep R Janagam, Timothy D Mandrell, James R Johnson, Tao L Lowe.   

Abstract

Although great efforts have been made to develop long-acting injectable hormonal contraceptives for more than four decades, few long-acting injectable contraceptives have reached the pharmaceutical market or even entered clinical trials. On the other hand, in clinical practice there is an urgent need for injectable long-acting reversible contraceptives which can provide contraceptive protection for more than 3 months after one single injection. Availability of such products will offer great flexibility to women and resolve certain continuation issues currently occurring in clinics. Herein, we reviewed the strategies exploited in the past to develop injectable hormonal contraceptive dosages including drug microcrystal suspensions, drug-loaded microsphere suspensions and in situ forming depot systems for long-term contraception and discussed the potential solutions for remaining issues met in the previous development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25899076     DOI: 10.1007/s11095-015-1686-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  57 in total

1.  Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions.

Authors:  C Berkland; K Kim; D W Pack
Journal:  J Control Release       Date:  2001-05-18       Impact factor: 9.776

2.  The development of depot contraceptives.

Authors:  R P Shearman
Journal:  J Steroid Biochem       Date:  1975-06       Impact factor: 4.292

Review 3.  Classification and comparison of oral contraceptives containing new generation progestogens.

Authors:  J R Newton
Journal:  Hum Reprod Update       Date:  1995-05       Impact factor: 15.610

4.  Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vitro evaluation.

Authors:  Z H Gao; A J Shukla; J R Johnson; W R Crowley
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

5.  Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking.

Authors:  Xiao Huang; Brigitta L Chestang; Christopher S Brazel
Journal:  Int J Pharm       Date:  2002-11-06       Impact factor: 5.875

6.  Biodegradation and biocompatibility of contraceptive-steroid-loaded poly (DL-lactide-co-glycolide) injectable microspheres: in vitro and in vivo study.

Authors:  Magharla Dasaratha Dhanaraju; Rajagopalan Rajkannan; Devarajan Selvaraj; Rajadas Jayakumar; Chandrasekar Vamsadhara
Journal:  Contraception       Date:  2006-04-19       Impact factor: 3.375

Review 7.  Female hormones and thrombosis.

Authors:  F R Rosendaal; F M Helmerhorst; J P Vandenbroucke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-02-01       Impact factor: 8.311

8.  PLG microsphere size controls drug release rate through several competing factors.

Authors:  Cory Berkland; Kyekyoon Kim; Daniel W Pack
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

9.  Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system.

Authors:  S R Jameela; T V Kumary; A V Lal; A Jayakrishnan
Journal:  J Control Release       Date:  1998-03-02       Impact factor: 9.776

10.  Risperidone long-acting injection.

Authors:  Pierre Chue
Journal:  Expert Rev Neurother       Date:  2003-07       Impact factor: 4.618

View more
  8 in total

1.  Biodegradable Polymeric Injectable Implants for Long-Term Delivery of Contraceptive Drugs.

Authors:  Ohan S Manoukian; Michael R Arul; Naseem Sardashti; Teagan Stedman; Roshan James; Swetha Rudraiah; Sangamesh G Kumbar
Journal:  J Appl Polym Sci       Date:  2017-11-29       Impact factor: 3.125

Review 2.  Beyond conventional antibiotics - New directions for combination products to combat biofilm.

Authors:  Danir Fanisovich Bayramov; Jennifer Ann Neff
Journal:  Adv Drug Deliv Rev       Date:  2016-08-03       Impact factor: 15.470

Review 3.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

4.  Impact of Formulation Parameters on In Vitro Release from Long-Acting Injectable Suspensions.

Authors:  Quanying Bao; Yuan Zou; Yan Wang; Stephanie Choi; Diane J Burgess
Journal:  AAPS J       Date:  2021-03-11       Impact factor: 4.009

5.  An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems.

Authors:  Dileep R Janagam; Lizhu Wang; Suryatheja Ananthula; James R Johnson; Tao L Lowe
Journal:  Pharmaceutics       Date:  2016-09-01       Impact factor: 6.321

6.  ELQ-331 as a prototype for extremely durable chemoprotection against malaria.

Authors:  Martin J Smilkstein; Sovitj Pou; Alina Krollenbrock; Lisa A Bleyle; Rozalia A Dodean; Lisa Frueh; David J Hinrichs; Yuexin Li; Thomas Martinson; Myrna Y Munar; Rolf W Winter; Igor Bruzual; Samantha Whiteside; Aaron Nilsen; Dennis R Koop; Jane X Kelly; Stefan H I Kappe; Brandon K Wilder; Michael K Riscoe
Journal:  Malar J       Date:  2019-08-27       Impact factor: 2.979

7.  Levonorgestrel Microneedle Array Patch for Sustained Release Contraception: Formulation, Optimization and In Vivo Characterization.

Authors:  Amarjitsing Rajput; Riyaz Ali M Osmani; Achyut Khire; Sanket Jaiswal; Rinti Banerjee
Journal:  Molecules       Date:  2022-04-06       Impact factor: 4.411

8.  Exploring Trehalose on the Release of Levonorgestrel from Implantable PLGA Microneedles.

Authors:  Xiaoyu Zhao; Suohui Zhang; Guozhong Yang; Zequan Zhou; Yunhua Gao
Journal:  Polymers (Basel)       Date:  2020-01-01       Impact factor: 4.329

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.